A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

NCT03000530 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depression

Interventions

DRUG: SAGE-217
DRUG: Placebo

Sponsor

Biogen